Can hepatitis c be cured in just 4 weeks? a new trial puts it to the test

NCT ID NCT03855917

Recruiting now ⭐️ CURE ⭐️ Sponsor: Kirby Institute Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This pilot study is testing whether a 4-week course of two antiviral drugs—sofosbuvir plus glecaprevir/pibrentasvir—can cure chronic hepatitis C in people who have not been treated before and have only mild liver scarring. Participants who relapse after the short treatment will receive a standard 12-week course of glecaprevir/pibrentasvir. The goal is to see if a shorter, simpler treatment regimen is effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of sofosbuvir and glecaprevir/pibrentasvir
What this could lead to: If successful, this could shorten hepatitis C treatment from the standard 8-12 weeks to just 4 weeks, making cure faster and more convenient.
What could go wrong: This is a small pilot study with only 30 participants, so results may not apply to everyone. There is a risk of virological relapse after such a short treatment course.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C

Contacts and locations

Locations

Blacktown Mt Druitt Hospital
RECRUITING

Sydney, New South Wales, 2148, Australia
Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 5000, Australia
St Vincent's Hospital
RECRUITING

Darlinghurst, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.